Trial Profile
Phase I trial of polyclonal antibodies, developed in Japan by AnGes MG using Vical's DNA vaccine technology, for the treatment of Ebola virus infection
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2015
Price :
$35
*
At a glance
- Drugs Polyclonal antibodies (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors AnGes
- 30 Jan 2015 New trial record
- 14 Jan 2015 AnGes has signed an agreement with Vical for the rights to develop and commercialise this product in Japan, and this trial is expected to be initiated in the first quarter of 2015, according to an AnGes MG media release.